Content about Claritin-D

June 7, 2013

The May/June 2013 Skin/itch Relief Ingredient Guide breaks down the indication, ingredients, purpose and dosage of AmLactin Moisturizing Body Lotion, CeraVe Renewing SA Cream, Olay Advanced Healing, Curel Itch Defense, Vaseline Intensive Rescue, Tecnu Extreme, Benadryl ExtraStrength Spray and Allegra Anti-itch Cream.

The May/June 2013 Skin/itch Relief Ingredient Guide breaks down the indication, ingredients, purpose and dosage of AmLactin Moisturizing Body Lotion, CeraVe Renewing SA Cream, Olay Advanced Healing, Curel Itch Defense, Vaseline Intensive Rescue, Tecnu Extreme, Benadryl ExtraStrength Spray and Allegra Anti-itch Cream.

April 4, 2013

The March/April 2013 Allergy Relief Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Claritin-D, Allegra-D, Zyrtec-D, Benadryl-D, Advil Allergy and Congestion Relief, UrgentRx Allergy Attack, Hyland's Seasonal Allergy Relief, Similasan's Nasal Allergy Relief and Boiron's Sabadil.

The March/April 2013 Allergy Relief Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Claritin-D, Allegra-D, Zyrtec-D, Benadryl-D, Advil Allergy and Congestion Relief, UrgentRx Allergy Attack, Hyland's Seasonal Allergy Relief, Similasan's Nasal Allergy Relief and Boiron's Sabadil.

February 22, 2012

Prescription-only pseudoephedrine regulation has no impact on the methamphetamine trade, according to a Cascade Policy Institute study on the 2005 Oregon law, which restricts access to medicines containing pseudoephedrine.

PORTLAND, Ore. — Prescription-only pseudoephedrine regulation has no impact on the methamphetamine trade, according to a Cascade Policy Institute study on the 2005 Oregon law, which restricts access to medicines containing pseudoephedrine.

February 14, 2012

Perrigo on Tuesday announced that it has begun shipping Loratadine-D 12-hour extended-release tablets.

ALLEGAN, Mich. — Perrigo on Tuesday announced that it has begun shipping Loratadine-D 12-hour extended-release tablets.

August 17, 2011

Perrigo is planning to launch more than 45 new products in fiscal 2012 that will translate into approximately $190 million added to annual Perrigo sales, Perrigo chairman, president and CEO Joe Papa told analysts during the company's fourth-quarter conference call Tuesday.

ALLEGAN, Mich. — Perrigo is planning to launch more than 45 new products in fiscal 2012 that will translate into approximately $190 million added to annual Perrigo sales, Perrigo chairman, president and CEO Joe Papa told analysts during the company's fourth-quarter conference call Tuesday.

And while none of these new over-the-counter private-label products will help reduce cholesterol levels, Papa did set the stage for a future store-brand equivalent to Pfizer's blockbuster statin Lipitor.